Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Immunovant
Company

Immunovant

Tracked across 1 events · 8 articles · First seen Apr 02, 2026 · Last active Apr 02, 2026

Sentiment
-70
Attention
4
Events
1
Relationships
1
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 -70
Business
Immunovant's Batoclimab Fails Phase 3 TED
Immunovant's batoclimab failed to meet its primary endpoint in Phase 3 studies for thyroid eye disease (TED), leading to a negative impact on the company's stock and development pipeline for this specific drug. The company will review future plans for batoclimab with HanAll Biopharma Co., Ltd. However, Immunovant remains focused on IMVT-1402 for other autoimmune diseases.
Apr 02, 2026 · 8 articles
Relationships (1)
HanAll Biopharma partner ↔ Immunovant Immunovant and HanAll Biopharma Co., Ltd. are partners in the development of bat
NEWSDESK
Track Immunovant live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.